@article{bbe23855bf84407d81594aaabdae2134,
title = "Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study",
abstract = "The Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST; NCT02953704) is an ongoing, noninterventional study assessing clinical characteristics and patient-reported outcomes (PROs) of patients with myelofibrosis (MF) or essential thrombocythemia (ET). This analysis assessed PROs at enrollment; symptom burden and quality of life (QoL), work productivity, and activity were assessed using validated questionnaires in patients with low- or intermediate-1-risk (age-alone) MF, or high- or low-risk ET (receiving ET-directed therapy) at enrollment. In MF and ET cohorts, fatigue had highest mean symptom score. Women had higher mean total symptom scores (TSS), mean symptom scores, and reduced QoL versus men. In patients with MF, mean TSS and symptom scores were similar between risk groups. Patients with low-risk ET had higher mean TSS and symptom scores than patients with high-risk ET. In conclusion, patients with lower risk MF and low- or high-risk ET experience significant symptom burden affecting QoL and ability to work.",
keywords = "essential thrombocythemia, Myelofibrosis, observational study, patient-reported outcomes, quality of life, symptom burden",
author = "Ellen Ritchie and Anas Al-Janadi and Craig Kessler and Robyn Scherber and Tricia Kalafut and Haobo Ren and Ruben Mesa",
note = "Funding Information: The authors wish to thank the patients and their families, the investigators, and the site personnel who participated in this study. Medical writing and editorial assistance were provided by Rachel Shparberg, PhD, of Envision Pharma Group (Philadelphia, PA, USA), and was funded by Incyte Corporation. Funding Information: Ellen Ritchie has a consulting role at Celgene, Incyte Corporation, Novartis, and Pfizer; participated in the speakers{\textquoteright} bureau for Ariad, Celgene, Incyte Corporation, and Novartis; received research funding from Astellas, Bristol Myers Squibb, Novartis, NS Pharma, and Pfizer; received travel support from Celgene and Novartis. Anas Al-Janadi holds honoraria from GSK and Karyopharm Therapeutics. Craig Kessler sits on the advisory board for Incyte Corporation and received research support from Incyte Corporation. Patricia Kalafut and Haobo Ren hold employment and stock ownership from Incyte Corporation. Robyn Scherber was a previous employee and stock owner of Incyte Corporation. Ruben Mesa has a consulting role at Incyte Corporation, La Jolla Pharmaceutical Company, Novartis, and Sierra Oncology; received research funding from AbbVie, Celgene, CTI Biopharma, Genotech Pharma, Incyte Corporation, Promedior, and Samus. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2022",
doi = "10.1080/10428194.2022.2113531",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
}